Genovation BioScience is a clinical-stage health care company with a chemistry driven approach to leveraging breakthrough protein science to treat disease and improve human health. It is our objective to utilize cutting edge artificial intelligence and data management to optimize the discovery and approval of new therapeutics and research tools.
WE DESIGN NANOPARTICLES WITH ANTIBODY-LIKE PROPERTIES
Protein affinity reagents (PARs), frequently antibodies, are essential tools for basic research, diagnostics, separations and clinical applications. Synthetic copolymer nanoparticles (NPs), engineered with affinity for specific protein targets, are abiotic alternatives to PARs which offer economic and timesaving advantages. We have pioneered the development of these abiotic materials with antibody-like affinity and selectivity for a wide range of proteins, peptides and cells. You can find more details about synthetic antibodies here.
HISTONE CAPTURE FOR SEPSIS THERAPY
Sepsis is a multiple organ dysfunction caused by the body's response to an infection. Although multiple inflammatory mediators are released into the bloodstream during sepsis, a spectrum of highly toxic mediators, such as the cationic proteins known as histones, can lead to lethal effects to the host. The average mortality rate for septic shock (the advanced stage of sepsis) is about 40 percent. Although the number of deaths from sepsis has been increasing, no recent treatments have resulted in significant improvement of the survival rate.
We recently completed in vivo studies for treatment of sepsis with a nonbiological synthetic hydrogel nanoparticle (NP) that absorbs and neutralizes a spectrum of cationic inflammatory mediators in the bloodstream of mice. These results reveal a potential for hydrogel nanoparticle sequestrants as a unique strategy for sepsis therapy using abiotic polymer nanogel NPs that are engineered to selectively absorb and neutralize cationic inflammatory mediators of sepsis. In addition, since preclinical results have been obtained with ex vivo blood purification therapies as adjuvant treatment for sepsis, the synthetic hydrogel polymers may also serve in this capacity for the selective removal of histones from circulation to help ameliorate organ injury.
ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
In healthy individuals VEGF promotes the growth of blood vessels. VEGF can, however, contribute to an overgrowth of blood vessels behind the retina, leading to degeneration of the macula and vision loss. One in five people over age 75 suffer from age-related macular degeneration (AMD), and currently the only effective treatment for the advanced "wet" form of AMD involves injections of VEGF inhibitors, typically humanized anti-VEGF antibodies, into the eye, every four to six weeks.
We have developed synthetic polymer NPs with nano-molar affinity to VEGF 165 . The NPs inhibit binding of the signaling protein to its receptor VEGFR-2, preventing receptor phosphorylation and downstream VEGF 165 -dependent endothelial cell migration and invasion into the extracellular matrix. In addition, the NPs inhibit VEGF-mediated new blood vessel formation in vivo. Importantly, the non-toxic NPs do not exhibit off target activity. The results support the assertion that abiotic polymers offer a new paradigm in the search for protein affinity reagents by providing many of the functions of their protein counterparts.
Chief Science Officer
Ken Shea is a former department chair and distinguished professor of chemistry at the University of California, Irvine. His research interests are in polymer chemistry, materials research, nanoscience and synthetic and mechanistic organic chemistry. He has mentored 75 PhD students and an equal number of post-doctoral and visiting scientists and published over 320 manuscripts. His distinctions include a Cambridge University Winston Churchill College Overseas Fellow, NIH Senior International Fellow, Sandia National Laboratories Visiting Scientist, a DuPont Visiting Research Scientist and an American Chemical Society Cope Scholar Awardee. He served as a Standing Member, Physical and Life Science Directorate External Review, Lawrence Livermore National Laboratories. He is a Fellow of the American Association for the Advancement of Science, a Fellow of the ACS Polymer Materials, Science and Engineering Division and the ACS Polymer Chemistry Division. He holds visiting professor appointments at Zhejiang University and Beijing Institute of Chemical Technology and currently serves on the Lawrence Livermore National Security, LLC Science & Technology Committee.
His hobbies include traveling, sweating in the gym and food. Perhaps because he enjoys diving he also likes to venture into new areas of research that are over his head. Classical music grounds him.
Chief Medical Officer
Dr. Lipkowitz is board certified by the American Academy of Ophthalmology and is an active member of the American Academy of Ophthalmology, the American Society of Retina Specialists, the New Jersey Retina Society, and both the New Jersey and Pennsylvania Academies of Ophthalmology. He has previously served as the Section Chairman of the Department of Ophthalmology at Capital Health System.
He has researched, published and lectured on numerous topics in ophthalmology, including diabetic retinopathy, age-related macular degeneration, endophthalmitis, retinal vascular disease, retinal drug toxicity and retinal detachment.
Vice President, Operations
Michelle Lee is a scientist who develops smart polymer nanoparticles as abiotic protein affinity reagents for early stage cancer diagnosis, protein purification and antidotes. She has extensive experience in materials science, chemistry research, microfluidic device design and fabrication and specializes in designing/engineering polymer materials for biotechnology, medical devices and engineering applications.
She has more than 20 high-profile scientific publications including Nature Chemistry, PNAS and JACS on topics covering polymer materials, polymer hybrid materials and liposomes.
She loves snowboarding, hiking, rock climbing and travelling and also enjoys spending her own time as a volunteer in NPOs to develop soft skills and help the community grow.
Chief Technology Officer
Darryl Sasaki's research interests focus on the development of supramolecular assemblies with novel chemical, physical, and mechanical properties for biosensors, switchable surfaces, and cell-mimetic materials. At Sandia National Laboratories, he joined the Organic Materials Aging group and contributed to work on chemical recognition and optical sensor materials. Several years later he became a founding member of the first biomaterials group at Sandia, enabling an expansion of research directions involving self-organization, biomolecule recognition, hierarchical assembly, and the dynamics of chemically and physically responsive supramolecular architectures.
Darryl's work has resulted in the development of hybrid materials with unique energy transport and phase switching behavior, as well as nanoparticle delivery systems for small molecule and biomacromolecule therapeutics.
Chief Data Officer
Michael Jemison earned his PhD in mathematics from Princeton University earlier this year. As a mathematician, Michael's research interests centered around topology and geometry. Now he is excited to leverage mathematics in the applied sciences. In particular, his interests include machine learning, AI, and data mining with an eye towards applications to real world evidence and drug discovery.
He enjoys going to the gym, making marinara sauce, and spending time with family.
Laurence Berger brings to the Company significant experience in strategic and operational leadership both in and out of the finance function.
From his early employment at the dawn of the biotech era under the supervision of the late Raymond Vernon at Harvard Business School, Larry has contributed to the expansion of the creation and understanding of the life sciences. Previously, he served as a key member of the corporate finance group at LF Rothschild Unterberg Towbin that managed the initial public offerings of the newly incubated companies Cetus Corp. and Genentech. Over the last forty years, he has advised a number of international corporate efforts and joint ventures in the field. Amongst many transactions, he organized the efforts at Rhone Poulenc s.a. that led to the creation of Sanofi-Aventis.
For twenty five years he was the Managing Partner of Vanderbilt Associates, an advisory firm and early stage private equity private firm. Subsequent to that experience, he was CEO and President of Thames Pharmacal, a manufacturer of both new drug and generic drugs with over 90 NDA and ANDA approvals.
Larry served as Senior Adviser to Cromwell Enterprises L.P., a private equity investment firm, from 2007 to 2016. Currently, he is Executive Partner of Berger Group International.
He serves of the Task Force on Science and Engineering at Harvard University in addition to his responsibilities at the Harvard Alumni Association. He also serves on the non profit boards of the First Step Initiatives and the Nature Conservancy.
Larry derives deep satisfaction from a life long passion for great music and a quest of some 55 years to hit a little round ball into holes in the illusive firmament of the countryside. He has followed that quest on five continents. Always with a caring dog at this side, he is the proud Dad of three wonderful children.